Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.
about
Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cellsRETRACTED: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunitiesPrognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?Age and diet affect gene expression profile in canine skeletal muscleGenomic and oncoproteomic advances in detection and treatment of colorectal cancerPersonalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept.The colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information.Antibody targeting of claudin-1 as a potential colorectal cancer therapy.Discovery and preclinical validation of drug indications using compendia of public gene expression data.Prediction of disease severity in patients with early rheumatoid arthritis by gene expression profiling.Specific extracellular matrix remodeling signature of colon hepatic metastases.RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients.Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis.Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer.Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivoHighly informative marker sets consisting of genes with low individual degree of differential expression.Identification of metastasis-associated genes in colorectal cancer using metaDE and survival analysisGreatwall promotes cell transformation by hyperactivating AKT in human malignancies.Establishment of a monoclonal antibody against a peptide of the novel zinc finger protein ZNF32 proved to be specific and sensitive for immunological measurementsInnovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies.Accomplishments in 2007 in biologic markers for gastrointestinal cancersA colorectal cancer classification system that associates cellular phenotype and responses to therapyUtility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer.ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan.Preoperative chemoradiotherapy in locally advanced rectal cancer: correlation of a gene expression-based response signature with recurrence.Next generation sequencing and a new era of medicine.Clinical biomarkers in oncology: focus on colorectal cancer.RIP140 increases APC expression and controls intestinal homeostasis and tumorigenesis.Implementing prognostic and predictive biomarkers in CRC clinical trials.Genomic approach towards personalized anticancer drug therapy.Gene and MicroRNA Expression Are Predictive of Tumor Response in Rectal Adenocarcinoma Patients Treated With Preoperative Chemoradiotherapy.Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs.PSG9 promotes angiogenesis by stimulating VEGFA production and is associated with poor prognosis in hepatocellular carcinoma.The role of drug profiles as similarity metrics: applications to repurposing, adverse effects detection and drug-drug interactions.A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.New Topoisomerase I mutations are associated with resistance to camptothecinPredictive tests for individualization of pharmacological cancer treatment.HIC1 Expression Distinguishes Intestinal Carcinomas Sensitive to Chemotherapy.Molecular profiling for personalized cancer care
P2860
Q24646343-C13890D3-4735-451B-A91D-01E0E0CB6DD9Q24651467-76F13E74-3B87-4B88-83A3-EC7C6C0CB38EQ26830362-58F9585C-4385-44C7-AC9D-8958AAEAA6F1Q27355444-D7A405BB-424A-4275-900E-188DD2A6A03AQ33425477-59C6CF39-C267-4B6D-997A-DB102D806B5EQ33530942-A430875B-6EFD-4081-BE85-3AEF2ABDCF94Q33776217-BA693167-D62A-44D0-93D1-428184ACD01CQ33850900-6F0B27C2-4175-4C98-B024-11DE4C7301EFQ33995422-99506E44-6676-4C56-9557-5035071C1DA3Q34177096-8D7D59B9-C6FC-4075-8B4A-90123F02125DQ34984735-8A1714D6-D753-461A-AA51-707B3133589BQ35010521-9A71F2C6-045B-468D-A197-0DDD5ADAD6DFQ35653768-9A9ED249-498C-4919-9F67-603B772867CCQ35742491-DAD1E70C-B7B6-40C6-8931-E91079858F2DQ35832549-EA6AE0E0-D85A-4BF3-AAED-A3DCF8633DD2Q36051757-61404BCF-4E24-4FDC-AD80-59C342E3FEC6Q36134749-51E94F58-1115-45FB-8884-33D10229A075Q36502358-9FDDB380-E2D2-4155-9CB2-5790FE8B7609Q36520892-93CF2D31-D52A-400A-9E56-DB64F1CC9AADQ36576993-C8511377-9813-4F4E-A9AA-8C866DD46352Q37035264-DED7F591-3751-4469-9EEC-13D9E65616A2Q37149168-6B6885B4-8084-4BA5-AFAF-363C3EEB973BQ37175913-B926F86C-8417-4B9A-969E-92588D595B60Q37262623-7AA3CC77-A795-4906-B432-B48645C3453AQ37287637-4817AA77-D427-4B4B-9F58-EBA7CEE6472CQ37398630-3AB83B9D-9260-4AFE-A639-71E9E88C4D3BQ37409165-E059A0A5-5909-40BB-BCBC-486C4950F746Q37523898-AB5C46A5-06AD-4010-8960-2F4CD1E37BEAQ37726604-FCE347C2-F685-4386-9D6E-0B955321D75FQ37842126-01779FB4-BEA4-41FB-BF19-8C5537EF3594Q37976828-86EDEC62-5454-4A2E-B6D4-06050130ED27Q38441043-F1E59D54-4FD9-436F-8321-989CAE02F967Q38513661-4D760B81-EB61-4917-8A87-08860DC290BFQ38721758-B0D19924-CD68-4C0F-AE53-FF90774E080EQ38856712-6B94B2A3-34F6-4E98-ABC6-B85D19125C6BQ39452744-5DAE641D-0088-4B77-9DC0-AD42F081CB21Q39534943-FD86B6F6-6C83-432F-AFFB-2C18DFD048EBQ40109282-2D968B21-AC78-4385-9FCB-5F82A8F4F335Q40250355-BA548203-4514-4D02-8C1D-28993E1560C8Q41630733-F4D43656-CCEB-48C5-BCCB-8DF1397CFC1B
P2860
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Gene expression signature in a ...... fluorouracil, and irinotecan.
@ast
Gene expression signature in a ...... fluorouracil, and irinotecan.
@en
type
label
Gene expression signature in a ...... fluorouracil, and irinotecan.
@ast
Gene expression signature in a ...... fluorouracil, and irinotecan.
@en
prefLabel
Gene expression signature in a ...... fluorouracil, and irinotecan.
@ast
Gene expression signature in a ...... fluorouracil, and irinotecan.
@en
P2093
P2860
P356
P1476
Gene expression signature in a ...... fluorouracil, and irinotecan.
@en
P2093
Andrew Kramar
Benjamin Leblanc
Bernard Pau
Caroline Bascoul-Mollevi
Caroline Fraslon
Corinne Bareil
Emmanuel Conseiller
Franck Molina
Frédéric Bibeau
Maguy Del Rio
P2860
P304
P356
10.1200/JCO.2006.07.4187
P407
P577
2007-03-01T00:00:00Z